Givosiran
Product Specifications
Product Name Alternative
ALN-AS1
UNSPSC Description
Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria[1][2].
Target Antigen
Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/givosiran.html
Purity
97.90
Solubility
10 mM in H2O
Smiles
[Givosiran]
Molecular Weight
16300.6 (AS: 7563.9 + SS: 8736.7)
References & Citations
[1]Scott LJ. Givosiran: First Approval. Drugs. 2020 Feb;80(3):335-339.|[2]Balwani M, et, al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020 Jun 11;382(24):2289-2301.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-132610/Givosiran-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-132610/Givosiran-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1639325-43-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items